linjc16/ctgov huggingface dataset:
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Study Overview
=================
Brief Summary
-----------------
To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.

Conditions
-----------------
Cytomegalovirus Retinitis, HIV Infections

Intervention / Treatment
-----------------
* Drug: Valganciclovir
* Drug: Ganciclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented AIDS diagnosis Newly diagnosed peripheral CMV retinitis More than 3 weeks of previous therapy for CMV retinitis

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Valganciclovir|nan|
|Drug: Ganciclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Bileacid Malabsorption and GLP-1 Secretion

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to examine the influence of BAM on postprandial GLP--1 secretion and glucose homeostasis, both with and without bile acid sequestration.

Official Title
-----------------
Bileacid Malabsorption and GLP-1 Secretion

Conditions
-----------------
Bileacid Malabsorption

Intervention / Treatment
-----------------
* Drug: cholestagel® (Colesevelam)
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Northern European origin Normal haemoglobin Age above 18 years and below 70 years Informed and written consent BMI > 23 kg/m2 and < 35 kg/m2 Normal fasting plasma glucose (FPG) < 6.5 mM) and glycated haemoglobin (HbA1c) < 48 mmol/mol Exclusion Criteria: Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >2 times normal values) or history of hepatobiliary disorder Gastrointestinal disease (except BAM), previous intestinal resection, cholecystectomy or any major intra-abdominal surgery First-degree relatives with diabetes Nephropathy (serum creatinine >150 µM and/or albuminuria Treatment with medicine that cannot be paused for 12 hours Hypothyroidism or hyperthyroidism Treatment with oral anticoagulants Active or recent malignant disease Any treatment or condition requiring acute or sub-acute medical or surgical intervention Lack of effective birth control in premenopausal women Any condition considered incompatible with participation by the investigators

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Healthy controls<br>Healthy controls found according to the protocol | Drug: cholestagel® (Colesevelam)<br>* 3750mg<br>Drug: Placebos<br>* 3750mg<br>|
| Other: Patients with BAM<br>Patients with bile acid malabsorption found according to the protocol | Drug: cholestagel® (Colesevelam)<br>* 3750mg<br>Drug: Placebos<br>* 3750mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GLP-1 |  | 240 min |
Remifentanil and Atropine for Intubation in Neonates

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that the use of a combination of Atropine and Remifentanil will safely facilitate non emergent intubation procedure as effectively as the protocol of Atropine, Fentanyl, and Succinylcholine.

Official Title
-----------------
Remifentanil and Atropine for Intubation in Neonates; a Randomized Controlled Trial

Conditions
-----------------
Endotracheal Intubation

Intervention / Treatment
-----------------
* Drug: Atropine/Remifentanil
* Drug: Fentanyl/Atropine/Succinylcholine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemodynamically stable neonates of any gestational age admitted to the Neonatal Intensive Care Unit at McMaster Children's Hospital requiring an elective endotracheal intubation was anticipated. Exclusion Criteria: Urgent intubations Cyanotic congenital heart lesions Anticipated difficult airway Concurrent or recently administered (within 3 hours of the procedure) intravenous opioid infusions Pre-existing hyperkalemia Family history of malignant hyperthermia Prior enrollment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Remifentanil<br>Atropine Remifentanil | Drug: Atropine/Remifentanil<br>* Atropine 20mcg/kg Remifentanil 3mcg/kg<br>|
| Placebo Comparator: Fentanyl<br>Atropine Fentanyl Succinylcholine | Drug: Fentanyl/Atropine/Succinylcholine<br>* Atropine 20mcg/kg Fentanyl 2mcg/kg Succinylcholine 2mg/kg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Successful intubation |  | 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to return of spontaneous respirations |  | 15 minutes | 
| Oxygen saturation |  | During the procedure up to 15 minutes | 
| Heart Rate |  | During the procedure up to 15 minutes | 
| Blood Pressure |  | During the procedure up to 15 minutes | 
| Intubation Condition |  | 15 minutes post procedure | 
| Evidence of Trauma |  | 15 minutes post procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Remifentanil, Endotracheal intubation, Premedication, Sedation, Endotracheal Intubation in Neonates
Study of the Natural Variation in Strokevolume

Study Overview
=================
Brief Summary
-----------------
We would like to investigate the natural variation in the strokevolume of the heart. At the same time we would like to find out the minimal number of heart cycles necessary to discover a 10% increase in strokevolume, after a fluid bolus of 200ml Voluven, when using Esophageal Doppler.

Detailed Description
-----------------
We would like to investigate the natural variation in the strokevolume(SV) of the heart. At the same time we would like to find out the minimal number of heart cycles necessary to discover a 10% increase in SV, after a fluid bolus of 200ml Voluven, when using Esophageal Doppler. Also we will compare the variation in SV both before and after the patients have been fluid optimized, using an algorithm of 10% increase in SV in order to receive another fluid bolus. The equipment used, will be the CardioQ from Deltex medical.

Official Title
-----------------
Study of the Natural Variation in Strokevolume, and Investigation in the Number of Cycles Necessary to Find a 10% Strokevolume Variation Using Esophageal Doppler

Conditions
-----------------
Stroke Volume Variation

Intervention / Treatment
-----------------
* Procedure: Esophagus Doppler monitoring
* Procedure: Fluid optimization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Planned abdominal surgery Exclusion Criteria: Oesophageal pathology, Age >90 yr or <18 yr, Alcohol abuse, Aneurism in thoracic aorta

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Esophagus Doppler monitoring|nan|
|Procedure: Fluid optimization|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Strokevolume variation before fluid optimization |  |  | 
| Strokevolume variation after fluid optimization |  |  | 
| Number of cycles needed in order to detect a 10% strokevolume increase after fluid bolus of 200ml Voluven. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stroke volume, SV variation, Esophagus Doppler, Goal Directed Therapy
Dexmedetomidine Versus Propofol Sedation in Flexible Bronchoscopy: A Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The study will evaluate clinical outcomes during bronchoscopy procedures with dexmedetomidine in comparison to propofol. The clinical outcomes that will be evaluated are: oxygen saturation, transcutaneous Pco2, blood pressure and complications

Official Title
-----------------
Dexmedetomidine Versus Propofol Sedation in Flexible Bronchoscopy: A Randomized Controlled Trial

Conditions
-----------------
Sedation Complication

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine
* Drug: Propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients in the age group 18 to 70 years requiring flexible bronchoscopic evaluation of the airway in the Pulmonary institute at Rabin medical center Exclusion Criteria: known or suspected allergy to any of the study drugs, seizure disorder, renal (with serum creatinine > 2 mg/dL) or hepatic impairment (elevated liver enzymes > 2 times normal), haemodynamic instability (bradycardia with HR < 50 bpm or hypotension with SBP < 90 mmHg), or seriously ill patients with American Society of Anesthesiologists' physical status above III
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomised controlled trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Dexmedetomidine<br>Dexmedetomidine will be used for sedation during bronchoscopy | Drug: Dexmedetomidine<br>* Dexmedetomidine will be used for sedation during bronchoscopy<br>|
| Placebo Comparator: Propofol<br>Propofol will be used for sedation during bronchoscopy | Drug: Propofol<br>* Propofol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of de-saturation events | Number of events during bronchoscopy when saturation level decreased under 90% | During the procedure | 
| Oxygen saturation time < 90% | Total time during the procedure that the oxygen saturation was under 90% | During the procedure |
Promoting Physical Activity Among Patients With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of a tailored, print-based physical activity intervention for patients diagnosed with type 2 diabetes.

Detailed Description
-----------------
Given the growing rates of type 2 diabetes and the documented benefits of physical activity in the treatment of this illness, further research is needed to examine methods of targeting this patient group to achieve improvements in physical activity behavior. The primary aim of this planning grant is to implement a pilot study examining the feasibility and efficacy of an individually-targeted, theoretically-based physical activity intervention for patients with type 2 diabetes. The physical activity intervention is compared to usual care, and the primary outcome is weekly physical activity at a one-month follow-up. These pilot data would demonstrate the feasibility of partnering with a community agency for participant recruitment and program implementation, as well as the potential efficacy of this intervention to promote physical activity in this high-risk population.

Official Title
-----------------
Promoting Physical Activity Among Patients With Type 2 Diabetes in a Community-Based Clinic

Conditions
-----------------
Type 2 Diabetes, Physical Activity

Intervention / Treatment
-----------------
* Behavioral: print-based physical activity intervention
* Behavioral: usual care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults diagnosed with type 2 diabetes current patients referred to diabetes center Exclusion Criteria: medical contra-indication to moderate-intensity physical activity

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: print-based physical activity intervention|individually-based, print-based physical activity intervention|
|Behavioral: usual care|print-based materials of nutritional information|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weekly physical activity |  | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| physical activity stage of change |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, physical activity, print-based intervention, tailored intervention
Treatment of CFS and Fibromyalgia With HRG 80 Red Ginseng

Study Overview
=================
Brief Summary
-----------------
Will a unique form of ginseng be clinically helpful in those with chronic fatigue syndrome and fibromyalgia?

Detailed Description
-----------------
Ginseng has been shown in earlier studies to help fatigue in a number of conditions. But because of overharvesting, most ginseng is no longer have optimal levels of the active ginsenosides. A new technique has been developed to restore the level of active ginseng components those found in the wild ginseng used in earlier studies. This is available in a form called HRG 80 Red Ginseng. The study is an open pilot study to explore whether this treatment would be helpful for improving clinical function and symptomatology in chronic fatigue syndrome and fibromyalgia. Current clinical experience is suggesting that it may be.

Official Title
-----------------
Treatment of CFS and Fibromyalgia With HRG 80 Red Ginseng

Conditions
-----------------
Fibromyalgia, CFS

Intervention / Treatment
-----------------
* Dietary Supplement: HRG 80 Red Ginseng


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be diagnosed with CFS and/or fibromyalgia live in the United States 3 - be over 18 years of age Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Open label study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active Ginseng treatment<br>People with CFS or Fibromyalgia will receive HRG 80 Red GInseng | Dietary Supplement: HRG 80 Red Ginseng<br>* A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite Visual analog scale of symptoms | Composite Score visual analog scale (0 - 30 Visual analog scale units , with 30 VAS units representing optimal function) of energy, cognition, and overall well-being. Each on a 0-10 scale with 10 being healthy. The units are the same for all 3 allowing them to be combined into a single composite total score. This total score (0-30 with 30 being the best outcome ) is the primary outcome measure | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS of pain and sleep | VAS of pain and sleep | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ginseng
Virtual Autopsy for Quality Control on Intensive Care Medicine

Study Overview
=================
Brief Summary
-----------------
The study aimed to compare CT-based virtual autopsy with classic autopsy as a tool for quality control in intensive care medicine.

Detailed Description
-----------------
The study aimed to compare CT-based virtual autopsy with classic autopsy as a tool for quality control in intensive care medicine. Especially with respect to complications during intervention like catheter pacement.

Official Title
-----------------
Virtual Autopsy for Quality Control on Intensive Care Medicine

Conditions
-----------------
Value of Virtual Autopsy for Quality Control in Icu

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >18 all patients dying in the icu during the study period Exclusion Criteria: relatives refuse participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| virtual and classic autopsy<br>Goldstandard: A group of patients in which virtual and classic autopsy is performed. | |
| virtual autopsy only<br>Intervention: A group of patients in which for various reasons virtual autopsy only is performed. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Occupational Therapy Trauma Informed Workshops and Consultations for Teachers at Head Start

Study Overview
=================
Brief Summary
-----------------
This study will utilize a pre/post mix method design Quantitative data will be gathered through surveys (including satisfaction questionnaires) administered pre/post workshops. Qualitative data will be obtained through interviews post- workshop and consultations.

Official Title
-----------------
Effectiveness of Occupational Therapy Trauma Informed Workshops and Consultations for Teachers at Head Start

Conditions
-----------------
Trauma

Intervention / Treatment
-----------------
* Other: Workshop


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Home Visitors or Teaching Staff at Head Start within San Bernardino County Between 18-65 years of age All genders English Speaking Exclusion Criteria: NA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Head Start Teachers<br>Participants will engage in three 1- hour workshops and optional consultations with an occupational therapist | Other: Workshop<br>* Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-Survey | knowledge and experience knowledge and experiences gained related to early childhood trauma. Higher scores indicate greater knowledge | Within 1 week after the consultations | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interview | Post interviews will be completed with participants who also complete the consultations | Within 2 weeks after the consultations | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
occupational therapy, trauma informed care